FTH
NASDAQFaeth Therapeutics Inc.
Faeth Therapeutics Inc. (FTH) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for FTH, including 3 SEC filings, 2 press releases and news items and 1 earnings update. The most recent was published Nov 6, 2026.
FTH rankings
Financial highlights
Full financials- Net income, TTM
- -$211.36M
- Free cash flow, TTM
- -$43.28M
- Cash
- $14.18M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks7+100%
2026-05-102026-11-01
Mix790d
- SEC Filings3(43%)
- Other2(29%)
- Earnings1(14%)
- Insider1(14%)
Activity · 52 weeks74 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
7 items- PRFaeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026Faeth Therapeutics (NASDAQ:FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual event on Monday, November 9 at 8:00 AM ET to discuss topline results from its Phase 2 PIK-201 trial exploring PIKTOR in advanced endometrial cancer. To register, click here. The event will feature key opinion leader and PIK-201 principal investigator David Starks, MD, MPH (Gynecologic Oncologist, Avera Cancer Institute), who will join company management to provide clinical perspectives on the unmet need and evolving treatment landscape in advanced endometrial cancer. A live question-an
- PRFaeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Faeth Therapeutics, Inc. (NASDAQ:FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 68,000 shares of the Company’s common stock in connection with their employment (collectively, the "Option Awards"). The Option Awards were granted effective November 4, 2026 pursuant to the Company’s 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance with Nasdaq Listing Rule 5635(c)(4).The Option Awards have an exercise price of $19.99 per share, equal to the closing price of the Company’s common stock on the grant date. The Option Awards will vest, with r
- INSIDERPresident and CEO Parikh Anand Kiran gifted 100,000 shares and received a gift of 100,000 shares, decreasing direct ownership by 12% to 717,699 units (SEC Form 4)4 - Faeth Therapeutics, Inc. (0001829802) (Issuer)
- SECSEC Form S-8 filed by Faeth Therapeutics Inc.S-8 - Faeth Therapeutics, Inc. (0001829802) (Filer)
- SECFaeth Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Faeth Therapeutics, Inc. (0001829802) (Filer)
- SECSEC Form 10-Q filed by Faeth Therapeutics Inc.10-Q - Faeth Therapeutics, Inc. (0001829802) (Filer)
- PRFaeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational UpdatesTopline results from the Phase 2 PIK-201 trial in endometrial cancer expected by year-end FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer Presented preclinical data on PIKTOR in HR+/HER2- breast cancer models at ESMO 2026 Faeth Therapeutics (NASDAQ:FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced financial results for the quarter ended September 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. "Since our last quarterly update, we presented PK/PD analysis that informed the PIKTOR dose in our Ph
FTH FAQ
9 questionsWhat does Faeth Therapeutics Inc. do?
Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., together with scientific founders Lewis Cantley, Ph.D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph.D.; Scott Lowe, Ph.D.; and...What is the latest news on FTH?
In the last 30 days Quantisnow tracked 7 wire items for FTH: 3 SEC filings, 2 press releases and news items, 1 earnings update and 1 insider trade. The most recent was published on November 6, 2026.Is FTH profitable?
No. Faeth Therapeutics Inc. reported a net loss of $211.36M for the twelve months ended Sep 30, 2026.How much cash and debt does FTH have?
Faeth Therapeutics Inc. reported $14.18M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does FTH stock trade?
Faeth Therapeutics Inc. (FTH) is listed on NASDAQ.What sector and industry is FTH in?
Faeth Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Faeth Therapeutics Inc. go public?
Faeth Therapeutics Inc. (FTH) completed its IPO in 2021.What companies are similar to FTH?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare FTH side-by-side with any of them on Quantisnow.How can I track FTH on Quantisnow?
Quantisnow aggregates Faeth Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FTH to receive live email and push alerts on every new disclosure.